BC Innovations | May 8, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice expressing a BSG mutation could be useful for screening therapies to treat early-onset high myopia. Whole-exome sequencing in 18 patients and their 36 unaffected parents identified 20 de novo heterozygous...
BC Innovations | Feb 2, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Malaria In vitro and cell culture studies identified a thermally stable P. falciparum Rh5 variant that could be used in malaria vaccines. The variant consisted of a C-terminal fragment of wild-type P. falciparum Rh5...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BC Innovations | Sep 10, 2015
Distillery Therapeutics

Therapeutics: Basigin Ok blood group (BSG; EMMPRIN; CD147); P. falciparum reticulocyte-binding protein homolog 5 (PfRh5)

Infectious disease INDICATION: Malaria Cell culture and mouse studies suggest inhibiting BSG could help treat malaria. A screen of mAbs from mice immunized with BSG ectodomains identified a mAb that decreased binding between BSG and...
BC Innovations | Jun 26, 2014
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection; meningitis Basigin Ok blood group (BSG; EMMPRIN; CD147); Neisseria meningitidis type IV pilus assembly protein (pilV); N. meningitidis major pilin PilE (pilE)...
BC Innovations | Jun 26, 2014
Targets & Mechanisms

Managing meningitis

SHX Vaccines is taking a new approach to vaccinating against meningitis-preventing meningococci from binding to host cells in the first place. The company's university collaborators have shown proof of concept for the approach in human...
BC Innovations | Dec 1, 2011
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRh5); basigin Ok blood group (BSG; EMMPRIN; CD147) In vitro studies suggest a vaccine targeting the malarial...
BC Innovations | Dec 1, 2011
Cover Story

Turning back the malarial hordes

Researchers from the Wellcome Trust Sanger Institute have identified a host receptor, basigin Ok blood group , that allows Plasmodium falciparum to invade erythrocytes and trigger a blood-stage malaria infection. 1 The researchers are now developing...
BC Innovations | Feb 17, 2011
Targets & Mechanisms

EMMPRIN's new clothes

EMMPRIN dropped off the drug discovery map in 2003 when Abgenix Inc. 's antibody against the target failed in a Phase II/III trial to treat graft-versus-host disease. Now, findings from Canadian researchers suggest it might...
BC Innovations | Feb 3, 2011
Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Basigin Ok blood group (BSG; EMMPRIN; CD147) Patient samples and mouse studies suggest that inhibiting EMMPRIN could...
Items per page:
1 - 10 of 29